Dear Editor,
We read with interest the paper by Lim and Wylie 1 published recently in Clinical and Experimental Dermatology, in which they proposed a possible association between an exanthema‐like eruption of the skin and the administration of the ChAdOx1 nCoV‐19 (AstraZeneca‐Oxford) COVID‐19 vaccine.
Adverse skin reaction to any drug or vaccine is possible. Regarding the new COVID‐19 vaccine, the pathomechanism is interesting. It is questionable whether there is any other possible cause of exanthema such as co‐infection by other viruses. Regarding this proposed adverse effect of the vaccine, a possible mechanism is the increase in blood viscosity after vaccination. 2 Exanthema‐like lesion is a possible uncommon clinical presentation of hyperviscosity. 3 , 4
Conflict of interest: the authors declare that they have no conflicts of interest.
Linked article: Lim PN, Wylie G. Clin Exp Dermatol 2021; doi: 10.1111/ced.14898.
References
- 1. Lim PN, Wylie G. Symmetrical drug‐related intertriginous and flexural exanthema like eruption associated with COVID‐19 vaccination. Clin Exp Dermatol 2021. 10.1111/ced.14898 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Joob B, Wiwanitkit V. Expected viscosity after COVID‐19 vaccination, hyperviscosity and previous COVID‐19. Clin Appl Thromb Hemost 2021; 27: 10760296211020833. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Anonymous . [Management of treatment‐related complications in patients with multiple myeloma: diarrhea, constipation, and rash.] (in Japanese). Nihon Rinsho 2016; 74 (Suppl): 447–51. [PubMed] [Google Scholar]
- 4. Paricio MF, Ghimire S, Binder A. Hyperviscosity in non‐IgM lymphoplasmacytic lymphoma. Med Form 2019; 20: 23–4. [Google Scholar]